<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="14665">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02915978</url>
  </required_header>
  <id_info>
    <org_study_id>INS002-16-092</org_study_id>
    <nct_id>NCT02915978</nct_id>
  </id_info>
  <brief_title>Fentanyl Sublingual Spray for the Treatment of Moderate to Severe Post-Operative Pain</brief_title>
  <official_title>A Phase 2 Multicenter, Randomized, Double-Blind, Multiple-Dose, Parallel-Group, Placebo-Controlled Study of Fentanyl Sublingual Spray for the Treatment of Moderate to Severe Post-Operative Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>INSYS Therapeutics Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>INSYS Therapeutics Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this trial is to evaluate analgesic efficacy of Fentanyl Sublingual
      Spray compared with placebo in participants with postoperative pain after a bunionectomy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2016</start_date>
  <completion_date type="Actual">February 10, 2017</completion_date>
  <primary_completion_date type="Actual">February 10, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Investigator</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Numeric Rating Scale (NRS) Summed Pain Intensity Difference (SPID) Over 0 to 48 Hours (NRS SPID-48) After Time 0</measure>
    <time_frame>Over 0 to 48 hours after Time 0</time_frame>
    <description>NRS SPID is calculated as a time weighted average of pain rated by the participant from 0 to 10 (&quot;no pain&quot; to &quot;worst pain imaginable&quot;).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>NRS Pain Intensity Difference (NRS PID) at Each Categorical Time Point After Time 0</measure>
    <time_frame>4 hours, 8 hours and 24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NRS Pain Intensity Score at Each Scheduled Time Point</measure>
    <time_frame>Baseline, 2.5, 5, 15, 30, and 45 minutes, and 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 12, 16, 20, 24, 32, 40, and 48 hours, and immediately before each use of rescue analgesia</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NRS SPID After Time 0</measure>
    <time_frame>Over 0 to 4 hours (NRS SPID-4), over 0 to 8 hours (NRS SPID-8), and over 0 to 24 hours (NRS SPID-24)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Pain Relief (TOTPAR) After Time 0</measure>
    <time_frame>Over 0 to 4 hours (TOTPAR-4), over 0 to 8 hours (TOTPAR-8), over 0 to 24 hours (TOTPAR-24), and over 0 to 48 hours (TOTPAR-48)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Onset of Analgesia</measure>
    <time_frame>Within 48 hours</time_frame>
    <description>Measured as time to perceptible pain relief confirmed by meaningful pain relief using the 2-stopwatch method (2 stopwatches will be started as soon as the first dose of study drug is administered. Each participant will be instructed to stop the first stopwatch when he or she experiences any perceptible pain relief and the second stopwatch when he or she experiences pain relief that is meaningful to them.)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Relief at Each Scheduled Time Point After Time 0 (First Dose of Study Medication)</measure>
    <time_frame>2.5, 5, 15, 30, and 45 minutes, and 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 12, 16, 20, 24, 32, 40, and 48 hours, as well as immediately before each use of rescue analgesia</time_frame>
    <description>Pain relief is determined on a 5-point categorical scale where 0=none, 1=a little, 2=some, 3=a lot, 4=complete.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Pain Relief From Time 0 (First Dose of Study Medication)</measure>
    <time_frame>Within 48 hours after Time 0</time_frame>
    <description>The highest level of pain relief achieved on a 5-point categorical scale where 0=none, 1=a little, 2=some, 3=a lot, 4=complete.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time (Minutes) to Peak Pain Relief From Time 0 (First Dose of Study Medication)</measure>
    <time_frame>Within 48 hours after Time 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time (Minutes) to First Perceptible Pain Relief From Time 0 (First Dose of Study Medication)</measure>
    <time_frame>Within 48 hours after Time 0</time_frame>
    <description>Time to perceptible and meaningful pain relief will be evaluated using the 2-stopwatch method (after the first dose only) (2 stopwatches will be started as soon as the first dose of study drug is administered. Each participant will be instructed to stop the first stopwatch when he or she experiences any perceptible pain relief and the second stopwatch when he or she experiences pain relief that is meaningful to them.)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time (Minutes) to Meaningful Pain Relief From Time 0 (First Dose of Study Medication)</measure>
    <time_frame>Within 48 hours after Time 0</time_frame>
    <description>Time to perceptible and meaningful pain relief will be evaluated using the 2-stopwatch method (after the first dose only) (2 stopwatches will be started as soon as the first dose of study drug is administered. Each participant will be instructed to stop the first stopwatch when he or she experiences any perceptible pain relief and the second stopwatch when he or she experiences pain relief that is meaningful to them.)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Using Rescue Medication</measure>
    <time_frame>Within 48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time (Hours) to First Use of Rescue Medication (Duration of Analgesia) Following Each Dose of the Investigational Product (IP)</measure>
    <time_frame>Within 48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Using Rescue Analgesia Over 0 to 24 Hours and Over 0 to 48 Hours</measure>
    <time_frame>Over 0 to 24 hours; over 0 to 48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participant Global Evaluation of Study Drug</measure>
    <time_frame>Within 48 hours</time_frame>
    <description>Participants provide a global evaluation of study drug on a 5-point categorical scale where 0=poor, 1=fair, 2=good, 3=very good, and 4=excellent.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Lower Dose Fentanyl</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lower dose Fentanyl delivered via sublingual spray every 4 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Higher Dose Fentanyl Sublingual Spray</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Higher dose Fentanyl delivered via sublingual spray every 4 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (matching Fentany) delivered via sublingual spray every 4 hours.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fentanyl</intervention_name>
    <description>Fentanyl delivered via sublingual spray</description>
    <arm_group_label>Lower Dose Fentanyl</arm_group_label>
    <arm_group_label>Higher Dose Fentanyl Sublingual Spray</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo delivered via sublingual spray</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Meets protocol-specified criteria for qualification and contraception

          -  Willing and able to remain confined in the study unit for the entire duration of each
             treatment period and comply with restrictions related to food, drink and medications

          -  Voluntarily consents to participate and provides written informed consent prior to
             any protocol-specific procedures

        Exclusion Criteria:

          -  History or current use of over-the-counter medications, dietary supplements, or drugs
             (including nicotine and alcohol) outside protocol-specified parameters

          -  Signs, symptoms or history of any condition that, per protocol or in the opinion of
             the investigator, might compromise:

               1. the safety or well-being of the participant or study staff;

               2. the safety or well-being of the participant's offspring (such as through
                  pregnancy or breast-feeding);

               3. the analysis of results
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giovanni DeCastro</last_name>
    <role>Study Director</role>
    <affiliation>INSYS Therapeutics Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arizona Research Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85023</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Anaheim Clinical Trials</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 23, 2017</lastchanged_date>
  <firstreceived_date>September 23, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fentanyl</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
